On 25 November 2025, Sanofi entered into a share purchase agreement to sell a 70% stake in the company operating its Lüleburgaz pharmaceutical manufacturing facility to Fareva, a world leader in industrial subcontracting for the pharmaceuticals, cosmetics, and industrial & household sectors. Sanofi will retain a 30% minority stake in the company.
The Lüleburgaz facility is one of Türkiye’s leading pharmaceutical manufacturing sites, with significant production capacity and export capabilities. The transaction is expected to close upon completion of customary regulatory approvals, including clearance from the Turkish Competition Authority.
Paksoy is pleased to announce that a team consisting of partner Stéphanie Beghe Sönmez, along with counsel Zeynep Toma and associates Selen Toma and Cansın Taner, is acting as counsel to Sanofi on this transaction.
Share
Related persons
You can contact us for detailed information.



Legal Information
This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.
You May Be Interested In
16 February 2026
Paksoy advised H.I.G. Capital on its acquisition of Atlas Dunnage
Paksoy advised H.I.G. Capital on its acquisition of Atlas Dunnage.
12 February 2026
Paksoy advised Tiryaki Agro on its acquisition of Savola Foods Turkey
Paksoy advised Tiryaki Agro on its acquisition of Savola Foods Turkey.
19 January 2026
Paksoy advises Amphenol on its acquisition of CommScope’s CCS business
Paksoy advises Amphenol Corporation on its acquisition of CommScope’s Connectivity and Cable Solutions (CCS) business.
14 January 2026
Paksoy advised Stellantis Group on the sale of BPF Pazarlama to TOFAŞ
Paksoy advised Stellantis Group on the sale of BPF Pazarlama to TOFAŞ.
13 January 2026
Paksoy advised IFC on its investment in Getmobil
Paksoy advised IFC on its investment in Getmobil.
12 January 2026
Mergermarket has ranked us #1 Legal Adviser in Turkey by deal value for 2025
Mergermarket has ranked us #1 Legal Adviser in Turkey by deal value for 2025, advising on USD 4.97 billion across 18 transactions.
